Covid symptoms have largely stayed the same over the last few years: cough, congestion, fever, a sore throat, nausea, ...

Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first ...

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA ...

Further, the company estimates that every clinical variant reported in the CDC COVID Tracker since the Omicron BA.1 lineage has been susceptible to pemivibart, even if untested, due to the ...

A detailed examination of how patients respond to the drug at various times and doses provides greater context to a recent ...

RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals Kavigale ...

VYD-2311 is under clinical development by Invivyd and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

Testing of samples from the 1950s demonstrated antibodies ... There are no treatments that have been clearly demonstrated to ...

Researchers have discovered that healthy skin — once thought to be a passive barrier — can actually produce antibodies that fight off infections. It’s hoped that the finding could one day lead to the ...

New findings from the NIH RECOVER Initiative suggest that SARS-CoV-2 infection may be associated with an increased risk of ME ...

Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), comments on the many viruses that could cause pandemics that are going around already.